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S UMMA R Y
OB J E C T I V E : To assess the feasibility of a streamlined
strategy for improving tuberculosis (TB) diagnostic
evaluation and treatment initiation among patients with
presumed TB.
DE S I GN : Single-arm interventional pilot study at five
primary care health centers of a streamlined, SIngle-
saMPLE (SIMPLE) TB diagnostic evaluation strategy: 1)
examination of two smear results from a single spot
sputum specimen using light-emitting diode fluorescence
microscopy, and 2) daily transportation of smear-
negative sputum samples to Xpertw MTB/RIF testing
sites.
R E S U LT S : Of 1212 adults who underwent sputum
testing for TB, 99.6% had two smears examined from
the spot sputum specimen. Sputum was transported for
Xpert testing within 1 clinic day for 83% (907/1091) of
the smear-negative patients. Of 157 (13%) patients with
bacteriologically positive TB, 116 (74%) were identified
using sputum smear microscopy and 41 (26%) using
Xpert testing of smear-negative samples. Anti-tubercu-
losis treatment was initiated in 142 (90%) patients with
bacteriologically positive TB, with a median time to
treatment of 1 day for smear-positive patients and 6 days
for smear-negative, Xpert-positive patients.
CONC LU S I ON : The SIMPLE TB strategy led to suc-
cessful incorporation of Xpert testing and rapid treat-
ment initiation in the majority of patients with
bacteriologically confirmed TB in a resource-limited
setting.
K E Y WORD S : tuberculosis; diagnosis; implementation
research; Xpert
PROMPT DIAGNOSIS AND TREATMENT of
tuberculosis (TB) patients is essential for making
progress towards TB elimination. However, 4.3
million of the estimated 10.4 million new cases in
2016 were not detected and reported to the World
Health Organization (WHO).1 There are three
overarching explanations for this large gap: TB
patients are not being notified to public health
authorities, they are not seeking care, or they are
not being diagnosed and treated even after seeking
care. The last explanation represents a clear health
system failure that is common in high-burden
countries: a recent systematic review found that up
to 38% of sputum smear-positive patients in Africa
are lost to follow-up before treatment initiation.2
Patients with smear-negative TB are even less likely to
complete a full diagnostic evaluation and be linked to
treatment.
A principal reason for these failures with regard to
care is the inadequacy of the current approach of
using smear microscopy for TB diagnosis at primary
health centers. First, smear microcopy has suboptimal
sensitivity, identifying only about 50% of patients
who actually have TB.3 Second, the typical process of
sputum collection and smear examination is burden-
some for patients. It requires multiple visits over
multiple days for testing, the receipt of results,
starting treatment or undergoing further work-up,PS and TN contributed equally to this article.
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and consumption of up to 3 months of household
income.4–8 It is not surprising that a substantial
proportion of patients do not complete this drawn-
out diagnostic process.9–12
To address these limitations, there has been
substantial donor investment in the scale-up of
Xpertw MTB/RIF (Cepheid, Sunnyvale, CA, USA), a
novel semi-automated molecular assay endorsed by
the WHO in 2010.13 Xpert identifies 90% of TB
cases within 2 h, and can be performed with minimal
human resource requirements.14 High cost and
infrastructure requirements, however, mean that the
majority of Xpert devices are being placed at district
or higher-level facilities13 accessed by ,15% of the
population.15 A cluster-randomized trial found that
current Xpert implementation did not impact mor-
tality; the main reason was the failure to link patients
with confirmed TB to treatment.16 Strategies for
improving referral to Xpert testing from peripheral
microscopy centers are essential to achieve access to,
utilization of and impact of Xpert on patient and
public health outcomes.
There is increasing evidence that behavioral theory
and implementation frameworks are useful for
identifying and targeting barriers to uptake of
guidelines.17 We previously conducted theory-in-
formed, mixed-methods studies to identify key
patient- and provider-level barriers to the uptake of
TB evaluation guidelines at health centers in Ugan-
da.18–20 Based on this formative assessment, we
identified two intervention components with strong
potential to improve guideline-based TB diagnosis: 1)
restructuring of clinic-level procedures via single-
sample (one specimen, two smears) light-emitting
diode (LED) fluorescence microscopy (FM),21 and 2)
daily sputum transport of smear-negative samples
and all human immunodeficiency virus (HIV) positive
samples to Xpert testing sites. Together these
interventions, known as the SIngle saMPLE (SIM-
PLE) TB evaluation strategy, are intended to reduce
the burden of sputum smear evaluation and Xpert
testing on patients and providers through a combi-
nation of behavior change and service delivery
interventions that are feasible within the local
context.
In this pilot study, we introduced the SIMPLE TB
strategy at five health centers in Uganda. Our
objective was to evaluate the feasibility and imple-
mentation of each component.
METHODS
Study setting and population
This single-arm interventional pilot study was con-
ducted at five peripheral health centers (level IV)
government health centers in rural Uganda. Level IV
health centers are the lowest level of the health system
where TB diagnosis (microscopy) and treatment are
available, covering a population of approximately
100 000. These services are provided free-of-charge
through the National Tuberculosis and Leprosy
Programme (NTLP). Health centers were included
in the pilot if they were 1) using standard (multi-day)
sputum smear microscopy as the primary method of
TB diagnosis; 2) participating in NTLP-sponsored
external quality assurance (EQA) for sputum smear
microscopy; and 3) affiliated with a district or
regional hospital offering Xpert testing. We collected
data on consecutive adults who were screened for
chronic cough (.2 weeks) by the health center and
who had sputum collected for TB diagnosis after the
introduction of the two SIMPLE TB strategy compo-
nents at each health center. Mycobacterial culture and
speciation were not routinely performed, as they are
not standard of care for TB diagnosis at the peripheral
health centers.
The study protocol was approved by the institu-
tional review boards of the University of California
San Francisco, San Francisco, CA, USA, and Maker-
ere University, Kampala, and by the Uganda National
Council for Science and Technology, Kampala,Ugan-
da.
Study procedures
Introduction of interventions
SIMPLE TB strategy components were introduced at
each health center during a 2-day site visit conducted
by research staff and NTLP staff. The health center
laboratory was provided with a Primo Star iLED
microscope (Zeiss Microscopy, Jena, Germany), and
laboratory officers were trained to perform LED FM
using the Uganda National Tuberculosis Reference
Laboratory (NTRL) training manual. Proficiency in
LED FM was checked by completion of a post-
training evaluation form and by practical examina-
tion by senior laboratory technologists who are
members of the research team. During the study
period, EQA for LED FM was performed on a
monthly basis by study staff and on a quarterly basis
by Uganda NTRL staff. A meeting was held with
clinical, laboratory and pharmacy staff to discuss
redesigning the TB microscopy process to facilitate
same-day diagnosis and treatment of smear-positive
TB. Key process changes included screening for cough
at the time of patient registration, immediate referral
of patients with chronic cough to the laboratory for
sputum collection before the clinician visit, on-
demand processing of sputum to prepare and analyze
two smears rather than batch processing, and training
additional staff to initiate TB treatment rather than
relying on a single TB pharmacist (Figure 1).
Transportation of residual sputum from smear-
negative samples and HIV-positive patients from
study health centers to Xpert referral hubs was
arranged by motorcycle (boda boda) on a daily,
rather than weekly, basis. Patients were instructed to
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return the following day to collect Xpert results. After
the initial 2-day visit, study staff visited the health
centers every month to reinforce training messages
and adherence to the intervention strategy.
Data collection
We extracted patient demographic and clinical data
monthly from routine health center records, including
laboratory and treatment registers, microscopy and
Xpert requisition forms, and GeneXpert software.
Individual patient records were matched across data
sources manually. Discrepancies were resolved
through discussion with health center staff. De-
identified patient data were entered into a secure
REDCap (Research Electronic Data Capture; Van-
derbilt University, Nashville, TN, USA) database.22
Data entered included HIV status, dates and results of
sputum smear examination, dates of sputum trans-
port to an Xpert testing facility, dates and results of
Xpert testing, and date of TB treatment initiation.
Smear- or Xpert-positive patients not recorded as
having started treatment .6 months after initial
sputum collection were contacted by telephone to
determine whether they had started treatment else-
where; for those who had, the information was
verified with the health center where the patient was
registered for treatment.
Outcomes
Outcomes for the present study were based on
process metrics that reflect implementation of the
SIMPLE TB algorithm components: numbers and
proportions of patients referred for TB testing who
had two smears examined from the spot specimen,
smear-positive patients who initiated anti-tuberculo-
sis treatment, smear-negative patients who had their
sputum sample referred for Xpert testing, and Xpert-
positive patients who initiated anti-tuberculosis
treatment. Additional outcomes included the time-
to-diagnosis and time-to-treatment of smear-positive
and Xpert-positive patients.
Data analysis
We described patient characteristics and the fidelity
of process implementation using proportions with
95% confidence intervals (CIs) for dichotomous
outcomes and either medians with interquartile
ranges (IQRs) or means with standard deviations
(SDs) for continuous outcomes. We compared differ-
ences in proportions across sites using the v2 test of
proportions. We performed all analyses using Stata,
version 14 (Stata Corporation, College Station, TX,
USA).
RESULTS
Demographic and clinical characteristics
Of 1212 adults (Table 1) who underwent sputum
testing for TB between February 2015 and April
2016, 684 (56%) were female; the median age was 40
years (IQR 30–50). HIV infection was documented in
Figure 1 SIMPLE TB diagnostic algorithm. The SIMPLE TB
algorithm calls for two smears from the spot sputum sample to
be prepared and examined. Patients with a positive sputum
smear should be initiated on treatment during their initial visit to
the health center. Patients with two negative smears or with HIV
infection should have the remainder of the spot sputum sample
sent for Xpert testing. Patients with positive Xpert results should
be started on treatment at their next visit to the health center. TB
¼ tuberculosis; HIV¼ human immunodeficiency virus; SIMPLE¼
SIngle-saMPLE.
Table 1 Demographic and clinical characteristics of the study group
Characteristic
All sites
(n ¼ 1212)
n (%)
Site 1
(n ¼ 357)
n (%)
Site 2
(n ¼ 148)
n (%)
Site 3
(n ¼ 194)
n (%)
Site 4
(n ¼ 230)
n (%)
Site 5
(n ¼ 283)
n (%)
Women 684 (56) 203 (57) 91 (61) 110 (57) 130 (57) 150 (53)
Age, years, median [IQR] 40 [30–50] 40 [30–50] 41 [30–52] 40 [30–51] 38 [30–50] 38 [30–49]
HIV status
Positive 647 (53) 223 (62) 77 (52) 81 (42) 121 (53) 145 (51)
Negative 504 (42) 133 (37) 43 (29) 104 (54) 102 (44) 122 (43)
Unknown 61 (5) 1 (0.3) 28 (19) 9 (5) 7 (3) 16 (6)
IQR¼ interquartile range; HIV¼ human immunodeficiency virus.
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647 (53%) patients. Patient demographics and
clinical characteristics were similar across study sites.
Testing for tuberculosis
Overall, 157 of 1212 (13%) patients had microbio-
logically confirmed (i.e., smear- and/or Xpert-posi-
tive) TB (Figure 2). Site-specific prevalence of
bacteriologically positive TB varied from 7% to
17%. The first smear result from the spot specimen
was positive in 113 (9.3%) patients, and the second
smear of the spot specimen identified three additional
smear-positive patients (116 positive smears) (incre-
mental yield 2.6%, 95%CI 0.5–7.4). Xpert testing
was performed for 995/1091 (91%) smear-negative
patients (median time to testing 1 day, IQR 0–2), and
41 additional patients with TB were identified
(incremental yield 26.1%, 95%CI 19.4–33.7). Ri-
fampin (RMP) resistance was not detected in any of
these smear-negative patients. Of all smear-negative
patients tested using Xpert, 61 (6.1%) had indeter-
minate/invalid results. Xpert testing was also per-
formed for 26/54 (48.1%) smear-positive patients
with documented HIV infection (median time to
testing 1 day, IQR 0–2): one was identified with RMP
resistance (one patient had an invalid/indeterminate
result).
Anti-tuberculosis treatment
Of 157 patients with bacteriologically positive TB,
142 (90.4%) were initiated on anti-tuberculosis
treatment (Figure 2): 107/116 (92.2%) patients
diagnosed using sputum smear microscopy and 35/
41 (85.4%) patients diagnosed using Xpert. Among
those treated, the median time to treatment was 1 day
(IQR 0–1) for smear-positive patients and 6 days
(IQR 2–11) for smear-negative, Xpert-positive pa-
tients. In addition, 17 patients were initiated on
treatment in the absence of a positive microbiological
test, with a median time to treatment of 4 days (IQR
0–249).
Adherence to the SIMPLE TB algorithm
Two smears were prepared and examined from the
spot sputum specimens of 1207 (99.6%) patients
(Figure 3). Of the 116 smear-positive patients, 50
(43.1%) started treatment at the initial health center
visit. The remaining sputum was referred for Xpert
testing within 1 clinic day for 907/1091 (83.1%)
sputum smear-negative patients. Of the 37 patients
who had a positive Xpert result, 28 (75.7%) started
anti-tuberculosis treatment within 2 weeks of their
initial health center visit. In addition, 23/54 (42.6%)
smear-positive patients with documented HIV infec-
tion had sputum referred for Xpert testing within 1
clinic day, in accordance with Xpert implementation
guidelines. One of these patients had RMP resistance
and was referred successfully to a treatment center for
multidrug-resistant TB.
There was some variability in adherence to the
SIMPLE TB algorithm across sites (Table 2). Com-
parison between sites showed that two smears were
examined in 98.6–100% of patients (P ¼ 0.24). For
smear-negative patients, sputum was transported to
the Xpert testing site within 1 clinic day for 77–88%
of smear-negative patients (P ¼ 0.002) and 17–67%
of smear-positive patients with documented HIV
infection (P ¼ 0.28). Anti-tuberculosis treatment
was initiated at the initial health center visit for 16–
73% of smear-positive patients (P ¼ 0.01) and
Figure 2 Overall tuberculosis diagnosis and treatment. The diagram describes the study flow and
outcomes for patients using the SIMPLE strategy. Of 1212 patients evaluated for TB using the
SIMPLE approach, 157 (13%) were microbiologically diagnosed. The majority of patients with
bacteriological diagnosis were started on treatment (90%); however, same-day treatment was
initiated in less than half of patients. *Treated for TB in the absence of a positive smear or Xpert
result. TB¼ tuberculosis; SIMPLE¼ SIngle-saMPLE.
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initiated within 2 weeks for 60–83% of smear-
negative, Xpert-positive patients (P¼ 0.56).
DISCUSSION
To reduce the burden of TB, strategies are needed to
facilitate the uptake of new diagnostics and ensure
that patients diagnosed with TB are linked to
treatment. In this pilot study, we evaluated a
streamlined TB diagnostic strategy that sought to
reduce the burden of diagnostic evaluations for TB on
patients and providers. We found that single-sample
LED FM and daily transport of smear-negative
samples to Xpert testing facilities are feasible in a
resource-limited setting with high TB prevalence.
Nearly all patients had two smears examined, and
91% of smear-negative patients underwent sputum
testing using Xpert. In addition, Xpert testing had
considerable incremental diagnostic yield, contribut-
ing to one quarter of all confirmed TB diagnoses.
However, even with a streamlined testing process,
10% of patients with bacteriologically positive TB
were not initiated on treatment, including 15% of
patients diagnosed based on Xpert results. Additional
strategies are needed to further reduce pre-treatment
loss to follow-up (LTFU).
Our findings highlight the continued importance of
sputum smear microscopy at peripheral health
centers where on-site Xpert testing is currently not
feasible. Sputum smear examination of a single spot
specimen identified 74% of all patients with bacte-
riologically positive TB and led to more rapid and
consistent linkage to treatment than occurred even
with daily referral of samples for Xpert testing. The
incremental yield of examining a second smear from
the spot specimen was only 2%. This is similar to the
3% incremental yield reported previously in Uganda
for single-specimen microscopy,23 but lower than the
11% incremental yield reported when a second smear
is prepared from a second sputum specimen.24
In settings with access to Xpert testing, our results
suggest that examination of a second smear—from
the same specimen or from a second specimen—may
not be necessary before referring for Xpert testing.
Daily transportation of sputum samples to Xpert
testing sites by boda boda was feasible, and the
incremental yield of Xpert testing was 26%—more
than twice that reported when performing smear
examination of a second sputum specimen in even the
most favorable evaluation.24 A single-specimen ap-
proach using the SIMPLE algorithm thus maximizes
diagnostic yield while minimizing workload and the
potential for LTFU. This approach should be consid-
ered as national guidelines begin shifting towards the
utilization of Xpert for all smear-negative patients.
Our streamlined diagnostic strategy also demon-
strated the potential to reduce pre-treatment LTFU.
At peripheral health centers in Uganda using a routine
TB diagnostic process, we found a pre-treatment
Figure 3 Adherence to the SIMPLE TB diagnostic algorithm.
The diagram describes the flow of patients through the SIMPLE
algorithm. Almost all patients referred for testing had two spot
sputum smears examined, with results. Same-day treatment
initiation for smear-positive patients and Xpert referral for HIV-
positive patients had moderate fidelity of implementation
(43%). The majority of smear-negative patients (83%) were
referred for Xpert testing in 1 day. These results suggest that a
facilitated TB diagnostic approach is feasible, particularly for
smear-negative patients. TB ¼ tuberculosis; HIV ¼ human
immunodeficiency virus; RIF ¼ rifampin; MDR-TB ¼ multidrug-
resistant TB; SIMPLE¼ SIngle-saMPLE.
Table 2 Site-level variation in implementation of the SIMPLE TB algorithm
Process metric
Site 1
(n ¼ 357)
n/N (%)
Site 2
(n ¼ 148)
n/N (%)
Site 3
(n ¼ 194)
n/N (%)
Site 4
(n ¼ 230)
n/N (%)
Site 5
(n ¼ 283)
n/N (%) P value*
Two smears examined from spot specimen 355 (99.4) 148 (100) 194 (100) 230 (100) 280 (98.9) 0.244
Sputum transported for Xpert testing
within 1 day if smear-negative
275/311 (88) 105/137 (77) 138/175 (79) 169/213 (79) 220/255 (86) 0.002
Treated on same day if smear-positive 20/44 (45) 8/11 (73) 8/19 (42) 10/17 (59) 4/25 (16) 0.01
Treated within 2 weeks if Xpert-positive 13/16 (81) 0/0 5/8 (63) 3/5 (60) 10/12 (83) 0.56
*Results of v2 analysis comparing proportions of patients evaluated using SIMPLE protocol components across sites.
SIMPLE¼ SIngle-saMPLE; TB¼ tuberculosis; HIV¼ human immunodeficiency virus.
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LTFU rate of 24% in smear-positive patients10 and
90% in smear-negative patients who had samples
transported to Xpert testing sites.25 In the present
study, pre-treatment LTFU was only 8% in smear-
positive patients. Moreover, 43% of smear-positive
patients started treatment during their initial health
center visit. Pre-treatment LTFU in smear-negative,
Xpert-positive patients remained high (15%), but
was substantially less than that observed in our
previous study.21 These results strongly suggest that
minimizing repeat visits to health centers to obtain a
diagnosis and initiate treatment is critical for reduc-
ing patient LTFU.
Because of the pilot nature of this study, there were
several potential limitations. First, it was not possible
to definitively attribute the improvements in process-
es that were observed to our intervention. A
randomized trial that includes a control group is
needed to confirm these findings. Second, pre-
treatment LTFU remained relatively high despite a
streamlined diagnostic process. This is consistent
with increasing evidence that guideline implementa-
tion requires multifaceted strategies to change behav-
ior.26 In addition to a streamlined diagnostic process,
future studies should evaluate interventions, such as
performance feedback, to target provider behavior
change and provide Xpert results by mobile telephone
text messages or incentives to target patient behavior
change. We are conducting a trial to evaluate on-site
molecular testing with a novel platform (GeneXpert
Omni; Cepheid27) in reducing barriers to same-day
diagnosis and treatment at primary health centers.
Studies assessing the costs and cost-effectiveness of
single-specimen microscopy and daily sputum trans-
portation to Xpert testing sites are ongoing.
CONCLUSION
A streamlined diagnostic process that involves the
collection of a single sputum specimen followed by
on-site examination of one smear and daily referral of
smear-negative specimens for Xpert testing is feasible
and has strong potential to improve TB diagnosis and
treatment at peripheral health centers. This approach
has a higher diagnostic yield and lower pre-treatment
LTFU than that reported for standard TB diagnostic
evaluation. Programs should consider future opera-
tional research of this approach while awaiting the
results of randomized trials.
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R E S U M E
O B J E C T I F : Evaluer la faisabilite´ d’une strate´gie
simplifie´e pour ame´liorer l’e´valuation du diagnostic et
la mise en route du traitement de la tuberculose (TB)
parmi les patients avec une pre´somption de TB.
S CH E´MA : E´tude pilote d’intervention a` un seul bras
dans cinq centres de soins de sante´ primaires d’une
strate´gie simplifie´e, l’e´valuation du diagnostic de TB sur
un seul e´chantillon, SIngle-saMPLE (SIMPLE) : 1)
examen de deux re´sultats de frottis d’un seul
e´chantillon de crachats graˆce a` un microscope en
fluorescence a` LED, et 2) transport quotidien
d’e´chantillons de crachats a` frottis ne´gatif vers les sites
de test Xpertw MTB/RIF.
R E´ S U LTAT S : Sur 1212 adultes qui ont eu un recueil de
crachats pour un test de TB, 99,6% ont be´ne´ficie´ de
deux frottis de l’e´chantillon de crachats examine´. Les
crachats ont e´te´ transporte´s pour le test Xpert en moins
d’un jour pour 83% (907/1091) des patients a` frottis
ne´gatif. Sur 157 (13%) patients avec une TB a`
bacte´riologie positive, 116 (74%) ont e´te´ identifie´s par
microscopie de frottis de crachats et 41 (26%) par un
test Xpert sur des e´chantillons a` frottis ne´gatif. Le
traitement de TB a e´te´ initie´ chez 142 (90%) patients
atteints de TB a` bacte´riologie positive, avec un de´lai
me´dian de traitement d’un jour pour les patients a` frottis
positif et de 6 jours pour les patients a` frottis ne´gatif,
Xpert positif.
CONC LU S I ON : La strate´gie TB SIMPLE a abouti a` une
incorporation re´ussie du test Xpert et a` une mise en route
rapide du traitement chez la majorite´ des patients
atteints de TB confirme´e par bacte´riologie dans un
contexte aux ressources limite´es.
R E S UM E N
OB J E T I VO: Evaluar la factibilidad de dinamizar la
estrategia de diagno´stico, evaluacio´n e iniciacio´n del
tratamiento de los pacientes con presuncio´n clı´nica de la
tuberculosis (TB).
M E´ TODO: Se llevo´ a cabo un estudio preliminar de
intervencio´n con un solo grupo experimental en cinco
centros de atencio´n primaria, sobre la dinamizacio´n de
la estrategia SIngle-saMPLE (SIMPLE) de evaluacio´n y
diagno´stico de la TB, que comportaba: 1) el examen con
microscopio LED de fluorescencia de los resultados de
dos baciloscopias a partir de una muestra inmediata
u´nica; y 2) el transporte diario de las muestras con
baciloscopia negativa a otro centro con el fin de
practicar la prueba Xpertw MTB/RIF.
R E S U LTA DO S: De los 1212 adultos en quienes se
recogieron muestras de esputo para la investigacio´n de
la TB, en el 99,6% se examinaron dos frotis de una
muestra inmediata. Las muestras se transportaron en el
dı´a de la consulta con el fin de practicar la prueba Xpert
en el 83% de los pacientes con baciloscopia negativa
(907/1091). De los 157 pacientes con TB confirmada
bacteriolo´gicamente (13%), 116 se detectaron mediante
el examen microsco´pico del frotis (74%) y 41 mediante
la prueba Xpert en las muestras con baciloscopia
negativa (26%). El tratamiento de la TB en 142
pacientes con confirmacio´n bacteriolo´gica (90%) se
inicio´ en un lapso mediano de un dı´a en los pacientes con
baciloscopia positiva y 6 dı´as en los pacientes con
baciloscopia negativa y prueba Xpert positiva.
CONC LU S I O´ N: La estrategia SIMPLE de deteccio´n de la
TB facilito´ la incorporacio´n eficaz de la prueba Xpert y
la ra´pida iniciacio´n del tratamiento en la mayorı´a de los
pacientes con TB confirmada bacteriolo´gicamente, en
un entorno de escasos recursos.
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